Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Go back to Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1| Merck & Co. (NYSE: MRK) | Delayed: 149.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.50 | 52 Week High | $65.46 | |||
| Open | $149.50 | 52 Week Low | $47.97 | |||
| Day High | $149.50 | P/E | 101.70 | |||
| Day Low | $149.50 | EPS | $1.47 | |||
| Volume | 20,529 | |||||
